An artificial-enzyme-equipped immunoregulator blocks platelet-mediated breast cancer hematogenous metastasis

Platelet activation and adhesion on the surface of circulating tumor cells (CTCs) assist them in surviving within the vasculature and acquiring enhanced migratory potential. Simultaneously, protected by surrounding/covering "micro-thrombi," CTCs evade immune surveillance in circulation, th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomaterials Jg. 322; S. 123380
Hauptverfasser: Hu, Ben, Lin, Huimin, Quan, Xiaolong, Sun, Fushan, Zhang, Fengling, Zhang, Fang, Wang, Yu, Chang, Yunhua, Wang, Jigang, Duan, Xiaohui, Yu, Meng
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Netherlands Elsevier Ltd 01.11.2025
Schlagworte:
Animals
Blood Platelets - drug effects
Blood Platelets - pathology
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cell Line, Tumor
Drug delivery
Female
Glucose oxidase
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
Nanomedicine
Neoplasm Metastasis
Neoplastic Cells, Circulating - drug effects
Neoplastic Cells, Circulating - pathology
Platelet inhibition
Tumor metastasis
Glucose oxidase
Drug delivery
Platelet inhibition
Nanomedicine
Tumor metastasis
ISSN:0142-9612, 1878-5905, 1878-5905
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Platelet activation and adhesion on the surface of circulating tumor cells (CTCs) assist them in surviving within the vasculature and acquiring enhanced migratory potential. Simultaneously, protected by surrounding/covering "micro-thrombi," CTCs evade immune surveillance in circulation, thereby promoting hematogenous tumor metastasis. Based on this, we designed a self-assembling nanoenzyme drug GSNO@B (NO donor-modified GOx self-assembled with the hydrophobic drug BMS-202) against platelet-mediated tumor metastasis. This strategy involves the depletion of glucose by GOx, which inhibits platelets activity and reduces forming the micro-aggregation. Concurrently, the nanoenzyme in situ releases NO further diminishes the protective adhesion and micro-aggregation of platelet on the tumor cells surface, thereby exposing them in shear forces and immune recognition in the circulatory system. Concurrently, the disintegration of the nanoenzyme GSNO@B releases the immune checkpoint inhibitor BMS-202, further facilitating the immune clearance of CTCs. Therefore, through a three-step strategy, GSNO@B effectively suppresses primary tumors growth and metastatic tumors formation by blocking the platelet-mediated hematogenous tumor metastasis pathway.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0142-9612
1878-5905
1878-5905
DOI:10.1016/j.biomaterials.2025.123380